Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 1
1992 2
1993 1
1994 4
1995 2
1997 1
1998 1
1999 2
2002 2
2003 1
2004 1
2005 1
2007 1
2008 3
2009 6
2010 10
2011 9
2012 7
2013 8
2014 15
2015 13
2016 15
2017 15
2018 12
2019 20
2020 22
2021 31
2022 25
2023 19
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
Chisari CG, Aguglia U, Amato MP, Bergamaschi R, Bertolotto A, Bonavita S, Morra VB, Cavalla P, Cocco E, Conte A, Cottone S, De Luca G, Di Sapio A, Filippi M, Gallo A, Gasperini C, Granella F, Lus G, Maimone D, Maniscalco GT, Marfia G, Moiola L, Paolicelli D, Pesci I, Ragonese P, Rovaris M, Salemi G, Solaro C, Totaro R, Trojano M, Vianello M, Zaffaroni M, Lepore V, Patti F; Italian MS Register Study Group. Chisari CG, et al. Among authors: moiola l. Neurotherapeutics. 2024 May 7:e00363. doi: 10.1016/j.neurot.2024.e00363. Online ahead of print. Neurotherapeutics. 2024. PMID: 38714462
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
Aprea MG, Schiavetti I, Portaccio E, Ballerini C, Bonavita S, Buscarinu M, Calabrese M, Cavalla P, Cellerino M, Cordioli C, Dattola V, De Biase S, De Meo E, Fantozzi R, Gallo A, Iasevoli L, Karabudak R, Landi D, Lorefice L, Moiola L, Ragonese P, Ruscica F, Sen S, Sinisi L, Signoriello E, Toscano S, Verrengia E, Siva A, Masciulli C, Sormani MP, Amato MP. Aprea MG, et al. Among authors: moiola l. Mult Scler. 2024 May;30(6):707-713. doi: 10.1177/13524585241232266. Epub 2024 Mar 8. Mult Scler. 2024. PMID: 38456445
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register. Bisecco A, et al. J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20. J Neurol. 2024. PMID: 37982852 Free PMC article.
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
Montini F, Nozzolillo A, Tedone N, Mistri D, Rancoita PM, Zanetta C, Mandelli A, Furlan R, Moiola L, Martinelli V, Rocca MA, Filippi M; Clinical SanRaf MS Study Group. Montini F, et al. Among authors: moiola l. J Neurol Neurosurg Psychiatry. 2024 Mar 13;95(4):342-347. doi: 10.1136/jnnp-2023-332073. J Neurol Neurosurg Psychiatry. 2024. PMID: 37857497
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F; Italian MS Registry. Chisari CG, et al. Among authors: moiola l. Neurotherapeutics. 2023 Oct;20(6):1696-1706. doi: 10.1007/s13311-023-01415-y. Epub 2023 Aug 23. Neurotherapeutics. 2023. PMID: 37610702 Free PMC article.
210 results